Skip to main content

Table 1 Time to reach 2-fold or 5-fold of the starting volume for the five different tumour models and 4 different treatment arms

From: Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts

  Carrier BIBW 2992 15f/15d + carrier 15f/15d + BIBW 2992
A7 -Glioblastoma
GDV2(95% C.I.) 6 d (6; 7) 6.5 d (4; 8) 16 d (7; 48) 59.5 d (24; 65)
ER/p-value 1.08/1.00 3.72/0.01
GDV5(95% C.I.) 12 d (11; 13) 16 d (13; 21) 56 d (53; 64) 67 d (56; 72)
ER/p-value 1.33/0.01 1.20/0.02
FaDu–SCC from the head and neck
GDV2(95% C.I.) 4 d (3; 5) 51 d (35; 65) 45 d (41; 48) 49 d (40; 52)
ER/p-value 12.75/<0.0001 1.09/0.63
GDV5(95% C.I.) 11.5 d (10; 16) 90 d (55;112) 54 d (47; 64) 56 d (49; 63)
ER/p-value 7.83/<0.0001 1.04/0.87
UT-SCC-14 – SCC from the head and neck
GDV2(95% C.I.) 7.5 d (6; 9) n. a. 50 d (41; 103) 61 d (51; 85)
ER/p-value n. a. 1.22/0.30
GDV5(95% C.I.) 21 d (17; 26) n. a. 65 d (53; 122) 91.5 d (79; 111)
ER/p-value n. a. 1.41/0.15
A431–SCC from the cervix
GDV2(95% C.I.) 4.5 d (4; 7) n. a. 38 d (5; 43) 72 d (64; 84)
ER/p-value n. a. 1.89/<0.0001
GDV5(95% C.I.) 14.5 d (9; 15) n. a. 62.5 d (52; 66) 122 d (64; 141)
ER/p-value n. a. 1.95/0.0050
UT-SCC-15 –SCC from the head and neck
GDV2(95% C.I.) 5 d (5; 8) n. a. 34 d (15; 42) 56.5 d (48; 148)
ER/p-value n. a. 1.66/0.03
GDV5(95% C.I.) 16 d (14; 20) n. a. 50 d (43; 100) 109 d (61; 182)
ER/p-value n. a. 2.18/0.04
  1. ER and p-values in comparison to control groups. n.a. – not applicable (tumours did not reach these endpoints).